Beijing Sun-Novo Pharmaceutical Research Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Why is Beijing Sun-Novo Pharmaceutical Research Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 16.25% and Operating profit at -8.91% over the last 5 years

Negative results in Sep 25

INTEREST(HY) At CNY 9.06 MM has Grown at 13.2%
NET SALES(Q) At CNY 265.46 MM has Fallen at -24.97%
PRE-TAX PROFIT(Q) At CNY 28.77 MM has Fallen at -56.22%

With ROE of 14.05%, it has a expensive valuation with a 6.69 Price to Book Value

Over the past year, while the stock has generated a return of 33.69%, its profits have fallen by -23.5%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Beijing Sun-Novo Pharmaceutical Research Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Beijing Sun-Novo Pharmaceutical Research Co., Ltd. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

13.3%

0.33

59.11%

China Shanghai Composite

23.86%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

16.25%

EBIT Growth (5y)

-8.91%

EBIT to Interest (avg)

18.77

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.08

Sales to Capital Employed (avg)

0.66

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

10.05%

Pledged Shares

Institutional Holding

ROCE (avg)

25.31%

ROE (avg)

16.49%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.95

EV to EBIT

58.84

EV to EBITDA

40.10

EV to Capital Employed

6.60

EV to Sales

6.66

PEG Ratio

Dividend Yield

ROCE (Latest)

11.22%

ROE (Latest)

11.14%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

NET PROFIT(HY)

At CNY 66.76 MM has Grown at 9,625.95%

NET SALES(HY)

At CNY 563.58 MM has Grown at 43.54%

RAW MATERIAL COST(Y)

Fallen by -13% (YoY

-17What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY 10.54 MM

INTEREST(9M)

At CNY 11.98 MM has Grown at 9.14%

INTEREST COVERAGE RATIO(Q)

Lowest at 527.56

DEBT-EQUITY RATIO (HY)

Highest at 15.09 %

NET SALES(Q)

Lowest at CNY 197.1 MM

OPERATING PROFIT(Q)

Lowest at CNY 17.79 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 9.02 %

PRE-TAX PROFIT(Q)

Lowest at CNY 16.3 MM

NET PROFIT(Q)

Lowest at CNY 20.63 MM

EPS(Q)

Lowest at CNY 0.19

Here's what is working for Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Raw Material Cost

Fallen by -13% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Operating Cash Flow

Lowest at CNY 10.54 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest Coverage Ratio

Lowest at 527.56

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest

At CNY 11.98 MM has Grown at 9.14%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

Lowest at CNY 197.1 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Net Sales

Fallen at -14.62%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit

Lowest at CNY 17.79 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 9.02 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at CNY 16.3 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Pre-Tax Profit

Fallen at -29.95%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit

Lowest at CNY 20.63 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

Net Profit

Fallen at -30.25%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

EPS

Lowest at CNY 0.19

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Debt-Equity Ratio

Highest at 15.09 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio